Recent 8-K filings for ATYR
Highest-materiality recent filing
aTyr Pharma Phase 3 EFZO-FIT study misses primary endpoint in pulmonary sarcoidosis
- Primary endpoint: change from baseline in mean daily OCS dose at week 48; p=0.3313 (2.79 mg efzofitimod vs 3.52 mg placebo).
- Nominal KSQ-Lung score improvement for 5.0 mg/kg vs placebo (p=0.0479); steroid withdrawal with KSQ-Lung improvement p=0.0199.
-
aTyr Pharma holders approve reverse stock split of 1-for-10 to 1-for-50 at Board's discretion
Proposal 1 approved: alternate charter amendments let the Board effect a reverse split at any ratio between 1-for-10 and 1-for-50, inclusive, in its sole discretion.
-
aTyr Pharma reaches FDA alignment on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
Study to start Q4 2026; global, randomized, double-blind, placebo-controlled, 54-week trial.
-
aTyr Pharma restructures: 60% workforce cut, CFO change, $58.9M cash, Phase 3 protocol pending FDA
Workforce reduction of ~60% and annualized opex savings of ~$13M starting Q4 2026.
-
aTyr Pharma regains global rights to efzofitimod after Kyorin termination
Kyorin terminated collaboration; aTyr and Kyorin entered termination agreement effective July 30, 2026.
-
aTyr Pharma receives Nasdaq extension to Nov 30, 2026 to cure bid price deficiency
Original bid price deficiency notice received Dec 4, 2025; stock closed below $1.00 for 30 consecutive days.
-
aTyr Pharma posts investor presentation highlighting efzofitimod for pulmonary sarcoidosis
Presentation covers efzofitimod (tRNA synthetase biologic) in pulmonary sarcoidosis and pipeline beyond.
-
aTyr Pharma reports $68.3M cash; plans Phase 3 for efzofitimod after FDA meeting
Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026.
-
aTyr Pharma to launch new Phase 3 study of efzofitimod in pulmonary sarcoidosis after FDA feedback
Cash, cash equivalents, and investments totaled $68.3M as of March 31, 2026 (unaudited).
-
aTyr Pharma FY2025 cash $80.9M; Phase 3 sarcoidosis study misses primary endpoint
Phase 3 EFZO-FIT missed primary endpoint (corticosteroid dose reduction at week 48), but showed benefit in KSQ-Lung (p=0.0479) and other secondary measures.
-
aTyr Pharma receives Nasdaq bid-price deficiency notice; 180 days to cure
On Dec 4, 2025, Nasdaq notified ATYR that its common stock closed below $1.00 for 30 consecutive business days.
-
aTyr reports Q3 results; Phase 3 efzofitimod miss but plans FDA meeting
Phase 3 EFZO-FIT missed primary endpoint of corticosteroid dose reduction at week 48; 5.0 mg/kg showed benefit on multiple quality-of-life measures.
-
aTyr Pharma Phase 3 EFZO-FIT study misses primary endpoint in pulmonary sarcoidosis
Primary endpoint: change from baseline in mean daily OCS dose at week 48; p=0.3313 (2.79 mg efzofitimod vs 3.52 mg placebo).
-
aTyr Pharma Phase 3 EFZO-FIT topline due mid-Sept; Q2 cash $83.2M, raised $30.7M ATM
Completed last patient visit in Phase 3 EFZO-FIT study for pulmonary sarcoidosis; topline results expected mid-September 2025.
-
aTyr completes Phase 3 EFZO-FIT last patient visit; topline data mid-September 2025
Last patient visit completed in Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis; topline data expected mid-September 2025.
-
aTyr Pharma reports Q1 cash of $78.8M; Phase 3 sarcoidosis data on track for Q3 2025
Cash, restricted cash and investments at $78.8M as of March 31, 2025; cash runway sufficient for one year after Phase 3 readout.
-
aTyr Pharma shareholders approve 5M share increase to equity plan; elect two directors
Stockholders approved amendment to 2015 Stock Plan, increasing share reserve by 5,000,000 to 15,719,300 shares.
-
aTyr Pharma reports year-end 2024 cash of $75.1M; Phase 3 topline data due Q3 2025
Cash, equivalents and investments $75.1M as of Dec 31, 2024; raised ~$18.8M via ATM after quarter-end.
-
On Dec 23, 2024, amended Open Market Sale Agreement with Jefferies to allow additional common stock sales.
-
aTyr Pharma appoints Eric Benevich to board; amends director compensation policy
Eric Benevich appointed as Class II director effective Dec 10, 2024, term through 2026 annual meeting.
-
aTyr Pharma completes Phase 3 enrollment in pulmonary sarcoidosis; topline data Q3 2025
Phase 3 EFZO-FIT enrolled 268 patients (target exceeded) at 85 centers in 9 countries; topline data expected Q3 2025.
-
aTyr Pharma completes Phase 3 sarcoidosis trial enrollment; Q2 cash $81.4M
Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolled 268 patients; topline data expected Q3 2025.
-
aTyr Pharma completes Phase 3 enrollment for efzofitimod; topline data Q3 2025
Enrolled 268 patients in EFZO-FIT study, exceeding target enrollment.
-
aTyr Pharma shareholders approve stock plan increase and report Phase 3 trial enrollment progress
Shareholders approved amendment to 2015 Stock Plan, increasing shares reserved by 3,000,000 to 10,713,670.
-
aTyr Pharma Q1 2024 update: Phase 3 EFZO-FIT completes enrollment expected in Q2 2024
Cash, cash equivalents, restricted cash and investments totaled $87.7 million as of March 31, 2024.
-
aTyr Pharma reports FY2023 cash $101.7M; Phase 3 sarcoidosis study enrollment to complete Q2 2024
Cash, equivalents, restricted cash, investments at Dec 31, 2023: $101.7M; cash runway through BLA filing.
-
Cash, cash equivalents and investments totaled $105.6M as of September 30, 2023.
-
aTyr Pharma initiates Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD
EFZO-CONNECT is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study in systemic sclerosis-associated ILD.
-
aTyr Pharma reports positive Phase 1b/2a post-hoc data for efzofitimod in sarcoidosis
Therapeutic doses (3.0 & 5.0 mg/kg) reduced steroid relapse rate to 7.7% vs 54.4% (p=0.017).
-
aTyr Pharma Q2 2023: cash $112M, R&D $9.8M; Phase 3 EFZO-FIT enrolling globally
Cash and investments $112.0M as of June 30, 2023; company expects cash runway into 2026.
-
aTyr Pharma stockholders approve doubling of authorized shares and equity plan increase
Authorized common shares increased from 85M to 170M via Charter Amendment filed May 18, 2023.
-
aTyr Pharma reports Q1 2023 cash of $117.6M; Phase 3 sarcoidosis trial enrolling
Cash, equivalents and investments of $117.6M as of March 31, 2023; $48.1M net from February stock offering.
-
aTyr Pharma holds less than 2% of cash at failed SVB; exposure limited
As of March 10, 2023, aTyr holds less than 2% of cash equivalents and investments at SVB.
-
Cash & investments $69.3M at Dec 31, 2022; Feb 2023 offering raised ~$52M gross plus $10M milestone from Kyorin; runway into 2026.
-
aTyr Pharma launches $50M public offering of 22.2M shares at $2.25; plans Phase 2 SSc-ILD study
Gross proceeds ~$50M from 22,225,000 shares at $2.25; underwriters have 30-day option for 3,333,750 additional shares.
-
aTyr Pharma's partner Kyorin doses first patient in Phase 3 EFZO-FIT study; receives $10M milestone
Kyorin dosed first patient in Japan in global pivotal Phase 3 EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis.
-
aTyr Pharma reports Q3 2022 cash $79.6M; Phase 3 sarcoidosis study initiated
Ended Q3 2022 with $79.6M in cash, restricted cash, cash equivalents and investments.
-
aTyr Pharma Q2 2022 cash $89.3M; initiates Phase 3 sarcoidosis study
Cash, restricted cash, cash equivalents and investments $89.3M as of June 30, 2022.
-
aTyr Pharma gets FDA Fast Track for efzofitimod in pulmonary sarcoidosis
FDA granted Fast Track designation on August 9, 2022 for lead candidate efzofitimod.
-
Phase 3 EFZO-FIT will enroll 264 patients; primary endpoint is steroid reduction; secondary endpoints include lung function and symptoms.
-
Lease term of 124 months starting April 1, 2023, with option to extend for 5 years.
-
aTyr Pharma Q1 2022 cash $98.7M; on track for registrational study in pulmonary sarcoidosis
Cash and investments $98.7M at March 31, 2022; R&D expenses $8.9M, G&A $3.5M.
-
aTyr Pharma stockholders approve doubling authorized shares to 85M
Stockholders approved increase in authorized common shares from 42.5M to 85,000,000.
-
aTyr Pharma entered into Open Market Sale Agreement with Jefferies LLC to sell up to $65M of common stock at market prices on Nasdaq.
-
FDA grants orphan drug designation to aTyr Pharma's efzofitimod for systemic sclerosis
FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
-
aTyr Pharma gets FDA orphan drug designation for efzofitimod in systemic sclerosis
FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
-
aTyr Pharma posts $107.9M cash; FDA path for efzofitimod registrational trial in Q3 2022
Cash, cash equivalents and investments of $107.9M as of Dec 31, 2021.
-
aTyr Pharma reports positive Phase 1b/2a results for ATYR1923; Q3 cash $116.4M
Positive proof-of-concept data for ATYR1923 in pulmonary sarcoidosis; registrational trial expected in 2022.
-
aTyr Pharma prices $75M public offering of 9.375M shares at $8.00 per share
Gross proceeds expected ~$75M from 9,375,000 shares at $8.00/share.
-
aTyr Pharma Announces Positive Phase 1b/2a Results for ATYR1923 in Pulmonary Sarcoidosis
ATYR1923 safe and well-tolerated with no drug-related serious adverse events in 37-patient pulmonary sarcoidosis trial.
-
aTyr Pharma Q2 cash $44.1M; sarcoidosis data readout expected mid-September
Cash, equivalents and investments $44.1M as of June 30, 2021; R&D expense $7.7M, G&A $2.8M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material